Inclusion Criteria:

1. Patient must have histologically or cytologically confirmed colorectal adenocarcinoma
or small bowel adenocarcinoma

2. Metastatic disease documented on diagnostic imaging studies with measurable disease
per RECIST version 1.1.

3. Refractory disease defined as: a) prior treatment with fluoropyrimidine, oxaliplatin,
irinotecan, and anti-EGFR therapy if KRAS wildtype for colorectal adenocarcinoma and;
b) prior treatment with fluoropyrimidine and oxaliplatin for small bowel
adenocarcinoma.

4. Colorectal adenocarcinoma patients must be known to have CpG island methylator
phenotype. CIMP-high phenotype will be defined as hypermethylation at 2 or more of
the 6 methylation-specific PCR markers (hMLH1, P16, P14, MINT1, MINT2, and MINT31).

5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.

6. Adequate organ function including: a) Absolute neutrophil count (ANC)
=/>1,500cells/mm^3; b) Platelets =/>100,000/ul; c) Hemoglobin >9.0 g/dL; d) Total
bilirubin =/<1.5mg/dL In patients with known Gilbert's syndrome, direct bilirubin
=/<1.5 x ULN will be used as organ function criteria, instead of total bilirubin; e)
AST and ALT < 2.5 x ULN; f) Alkaline phosphatase <2.5x ULN; g) Creatinine <1.5 gm/dL.

7. Negative serum or urine pregnancy test in women with childbearing potential (WOCBP)
defined as not post-menopausal for 12 months or no previous surgical sterilization,
within one week prior to initiation of treatment. WOCBP must be using an adequate
method of contraception to avoid pregnancy throughout the study and for up to 12
weeks after the last dose of study drug to minimize the risk of pregnancy.

8. A male subject of fathering potential must use an adequate method of contraception to
avoid conception throughout the study and for up to 12 weeks after the last dose of
study drug to minimize the risk of pregnancy. If the partner is pregnant or
breastfeeding, the subject must use a condom.

9. Patients must sign an Informed Consent and Authorization indicating that they are
aware of the investigational nature of this study and the known risks involved.

10. Patient is =/>18 years of age on the day of consenting to the study.

Exclusion Criteria:

1. Peripheral neuropathy of grade 2 or greater by Common Terminology Criteria for
Adverse Events (CTCAE) 4.0. In CTCAE version 4.0 grade 2 sensory neuropathy is
defined as "moderate symptoms; limiting instrumental activities of daily living
(ADLs)".

2. Prior treatment with taxane therapy for either colorectal cancer or small bowel
adenocarcinoma.

3. Chemotherapy or any other investigational agents within 14 days of first receipt of
study treatment, or major surgery within 28 days of first receipt of study treatment,
or palliative radiation within 7 days of first receipt of study treatment.

4. Concurrent severe and/or uncontrolled medical conditions which could compromise
participation in the study such as unstable angina, myocardial infarction within 6
months, unstable symptomatic arrhythmia, uncontrolled diabetes, serious active or
uncontrolled infection.

5. Pregnancy (positive pregnancy test) or lactation.

6. Patients with carcinomatous meningitis.

7. Known CNS disease, except for treated brain metastasis. Treated brain metastases are
defined as having no evidence of progression or hemorrhage after treatment and no
ongoing requirement for dexamethasone, as ascertained by clinical examination and
brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose)
are allowed. Treatment for brain metastases may include whole brain radiotherapy
(WBRT), radiosurgery (RS; Gamma Knife, LINAC, or equivalent) or a combination as
deemed appropriate by the treating physician. Patients with CNS metastases treated by
neurosurgical resection or brain biopsy performed within 3 months prior to Day 1 will
be excluded.